Triple Negative Breast Cancer News and Research

RSS

Income level impacts tumor recurrence and survival in women with ER-positive breast cancer

Patients with early-stage estrogen receptor-positive breast cancer who live in low-income neighborhoods are likelier to have more-aggressive tumors and significantly lower overall survival (OS) than those in higher-income neighborhoods, according to research led by Roswell Park Comprehensive Cancer Center.

21 Feb 2023

Cleveland Clinic researchers launch the next step in triple-negative breast cancer vaccine study

Cleveland Clinic researchers have launched the next step in their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

8 Feb 2023

Adding veliparib to chemotherapy can extend progression-free survival in patients with “BRCA-like” breast cancer

Results from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free survival (PFS) times in patients with triple-negative breast cancer (TNBC) that has a "BRCA-like" phenotype.

31 Jan 2023

Researchers develop new way to increase the potency of cancer vaccines

A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology (IIN) at Northwestern University.

31 Jan 2023

CAR T cell therapy may enhance the effectiveness of surgery for solid tumors

CAR T cell therapy, an approach which reprograms patients' own immune cells to attack their blood cancers, may enhance the effectiveness of surgery for solid tumors, according to a preclinical study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

11 Jan 2023

Immune system B-cells may be better in predicting HER2-positive breast cancer treatment response

Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have found that measuring activation of immune-system B cells may be better than measuring either T-cell activation or the total number of immune cells in and around a tumor, called tumor-infiltrating lymphocytes (TILs), in predicting whether HER2-positive breast cancer responds to treatment.

5 Jan 2023

New method uses artificial DNA to target and kill cancer cells

Researchers at the University of Tokyo have used artificial DNA to target and kill cancer cells in a completely new way.

21 Dec 2022

Researchers modulate the activity of potential therapeutic target for triple-negative breast cancer

Less than 20% of diagnosed breast cancers are designated "triple-negative," lacking three types of receptors often found in other breast cancer types.

30 Nov 2022

Study provides a more accurate tool to stratify patients with HER2-positive breast cancer

Patients with a type of breast cancer called HER2-positive are less likely to survive if their initial treatment fails to eradicate the tumor completely and they have high levels of immune cells called tumor-infiltrating lymphocytes in the residual disease.

21 Nov 2022

New therapeutic windows for developing effective treatments for metastatic tumors

Cancer that splits and develops in new organs around the body becomes significantly more difficult to fight. Now, researchers at Chalmers University of Technology, Sweden, have shown that these metastatic cancers, that spread from the original, adapt their metabolism to the tissue in which they grow. The discovery represents a breakthrough for the understanding of metastatic cancer and is an important piece of the puzzle in the search for more effective treatments.

17 Nov 2022

Popular dietary supplement linked to cancer risk, brain metastasis

Nanotechnology platform can make solid tumor cells more receptive to immunotherapy

A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy.

10 Nov 2022

UT Southwestern study uncovers a causative signaling pathway in breast cancer

UT Southwestern researchers have identified a causative signaling pathway in breast cancer, providing potential new targets for treatment of the most common type of cancer in women.

1 Nov 2022

Researchers find the root of immunosuppression and chemoresistance in TNBC tumors

Triple-negative breast cancer (TNBC) tumors gain immunosuppression and chemoresistance through interactions between interleukin 34 and myeloid-derived suppressor cells, researchers find.

1 Nov 2022

BCRF renews funding to support the development of novel therapeutics for triple-negative breast cancer

The Breast Cancer Research Foundation (BCRF) has renewed its funding to Elisa Port, MD, and Hanna Irie, MD, PhD, to study new therapeutic approaches that target aggressive triple-negative breast cancer.

31 Oct 2022

Cleveland Clinic awarded $12 million NIH grant to define how cytokines regulate inflammation

Cleveland Clinic's Lerner Research Institute was awarded a five-year $12 million grant by the National Cancer Institute, part of the National Institutes of Health, to define how cytokines - proteins produced during immune response - regulate inflammation and interact with cells and molecules surrounding tumors.

28 Oct 2022

Triple Negative Breast Cancer News and Research

Income level impacts tumor recurrence and survival in women with ER-positive breast cancer

Cleveland Clinic researchers launch the next step in triple-negative breast cancer vaccine study

Adding veliparib to chemotherapy can extend progression-free survival in patients with “BRCA-like” breast cancer

Researchers develop new way to increase the potency of cancer vaccines

CAR T cell therapy may enhance the effectiveness of surgery for solid tumors

Immune system B-cells may be better in predicting HER2-positive breast cancer treatment response

New method uses artificial DNA to target and kill cancer cells

Researchers modulate the activity of potential therapeutic target for triple-negative breast cancer

Study provides a more accurate tool to stratify patients with HER2-positive breast cancer

New therapeutic windows for developing effective treatments for metastatic tumors

Popular dietary supplement linked to cancer risk, brain metastasis

Nanotechnology platform can make solid tumor cells more receptive to immunotherapy

UT Southwestern study uncovers a causative signaling pathway in breast cancer

Researchers find the root of immunosuppression and chemoresistance in TNBC tumors

BCRF renews funding to support the development of novel therapeutics for triple-negative breast cancer

Cleveland Clinic awarded $12 million NIH grant to define how cytokines regulate inflammation

Newly developed chemical compounds show promise as potential anticancer therapy

Study shows potential for eliminating surgery in a small subset of breast cancer patients

UArizona researchers working on a less toxic treatment for deadly breast cancer

Researchers set sights on a new therapeutic target for aggressive breast cancer

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News